Neglected Tropical Diseases Diagnosis Market to Reach USD 12.35 Billion by 2034, Growing from USD 7.19 Billion in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - The neglected tropical diseases diagnosis market is defined by a persistent mismatch: the countries with the highest burden of NTDs are often the least able to afford the advanced diagnostic tools needed to detect them. That affordability gap is shaping how the market develops, pushing public health systems, NGOs, and diagnostic manufacturers toward more accessible, cost-effective testing solutions. Even so, the global neglected tropical diseases diagnosis market was valued at USD 7.19 billion in 2025 and is projected to reach USD 12.35 billion by 2034, growing at a CAGR of 6.2% during the 2026-2034 forecast period. The findings are detailed in a new report from Strategic Revenue Insights Inc., led by analyst Rohan Mehta. The research is based on primary interviews with diagnostic manufacturers, public health officials, and stakeholders at hospitals, NGOs, and research institutes, supplemented by secondary data collection across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Takeaways

• The neglected tropical diseases diagnosis market was valued at USD 7.19 billion in 2025 and is forecast to reach USD 12.35 billion by 2034, growing at a CAGR of 6.2%.
• Rapid diagnostic tests and PCR are highlighted as the leading diagnostic technologies, valued for speed in underserved settings and high sensitivity for detecting low pathogen levels, respectively.
• The integration of digital technologies and artificial intelligence into diagnostic processes is a key trend, expected to improve the accuracy and efficiency of NTD diagnosis.
• Brazil leads the countries covered at approximately USD 1.2 billion, while Indonesia is the fastest-growing country covered, expanding at a 10% CAGR.
• Abbott, bioMérieux, and Thermo Fisher Scientific are named among the leading companies in the competitive landscape.

Full report access: https://www.strategicrevenueinsights.com/industry/neglected-tropical-diseases-diagnosis-market

Closing the Diagnostic Gap: Access, Technology, and Public-Private Collaboration

Rising prevalence of NTDs in tropical and subtropical regions, combined with growing government and NGO initiatives to combat these diseases, is driving demand for accurate and timely diagnostic solutions. Technological advancements in diagnostic tools, including PCR and rapid diagnostic tests, are improving the speed and reliability of results, which is critical given that timely diagnosis is essential for effective treatment. Increasing investment in healthcare infrastructure and research and development activity is expected to continue creating opportunities for market participants.

Collaboration between public and private stakeholders is emerging as a central theme in the market's development. Partnerships between governments, NGOs, and private diagnostic companies are working to develop cost-effective solutions accessible to low-income populations, addressing one of the market's core structural challenges. The integration of digital technologies and artificial intelligence into diagnostic workflows is also expected to enhance accuracy and efficiency, while the expansion of telemedicine and remote diagnostics is improving access to testing in remote and underserved areas.

At the same time, growth is tempered by real constraints. Limited awareness and education about NTDs in certain regions can lead to underdiagnosis and undertreatment, while the high cost of advanced diagnostic technologies can restrict adoption precisely where the burden of disease is highest. Regulatory hurdles and the need to meet stringent quality standards add further complexity for manufacturers bringing new diagnostic products to market.

Market Segmentation

By Disease Type: The market is segmented into leishmaniasis, chikungunya, dengue, and sleeping sickness. Leishmaniasis diagnosis is in high demand across tropical and subtropical regions, chikungunya and dengue diagnostics are seeing rising demand particularly in Asia and Latin America, and sleeping sickness, concentrated in Africa, requires specialized diagnostic tools for early detection. The source content does not provide segment-level dollar or CAGR figures for this axis.

By Technology: The market includes rapid diagnostic tests, PCR, immunoassays, and microscopy. Rapid diagnostic tests are valued for delivering quick, accurate results in remote and underserved areas, while PCR offers high sensitivity and specificity for detecting low levels of pathogens. Immunoassays and microscopy remain widely used for reliable, accurate diagnosis. The source content does not provide segment-level dollar or CAGR figures for this axis.

By End Use: Public health labs, hospitals, NGOs, and research institutes make up the end-use segment. Public health labs handle large-scale testing and surveillance, hospitals provide diagnostic services to individual patients, and NGOs and research institutes are active in developing and deploying diagnostic solutions, often in collaboration with governments and international organizations. The source content does not provide segment-level dollar or CAGR figures for this axis.

By Product Type: The market spans kits, instruments, reagents, and services. Kits offer a convenient, cost-effective testing option, instruments provide high precision and accuracy, reagents are essential to conducting diagnostic tests, and services support the maintenance and operation of diagnostic equipment. The source content does not provide segment-level dollar or CAGR figures for this axis.

Regional Outlook

The report covers Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa, with detailed figures provided at the country level. Brazil leads the countries covered, with a market size of approximately USD 1.2 billion and a 7% CAGR, driven by the country's large population, high NTD prevalence, and government initiatives to strengthen healthcare infrastructure and awareness. India follows at approximately USD 1 billion with an 8% CAGR, supported by a high disease burden and rising healthcare infrastructure investment, particularly in rural and underserved areas. Nigeria, representing Africa, stands at approximately USD 800 million with a 9% CAGR, driven by high NTD prevalence and international efforts to combat these diseases. Indonesia is the fastest-growing country covered, at approximately USD 700 million and a 10% CAGR, supported by its large population and government initiatives to expand healthcare access. Saudi Arabia, representing the Middle East, stands at approximately USD 600 million with a 6% CAGR, driven by investment in healthcare infrastructure and research and development.

Competitive Landscape

Abbott is recognized for its wide range of diagnostic products, with particular strength in rapid diagnostic tests and immunoassays for NTDs. bioMérieux is noted for innovative diagnostic solutions and a strong global presence, with a focus on expanding its offerings through strategic partnerships. Thermo Fisher Scientific offers a comprehensive range of diagnostic products and services and is committed to improving healthcare access in underserved regions, while Roche is recognized as a global diagnostics leader active in research and development to address NTD-specific challenges. BD focuses on developing diagnostic solutions tailored to the specific needs of the NTD market. Cepheid, Sysmex, Standard Diagnostics, Bio-Rad Laboratories, and DiaSorin round out the competitive field, each investing in research and development and expanding their presence in emerging markets where demand for NTD diagnostics is rising.

Market Restraints

Limited awareness and education about NTDs in certain regions can lead to underdiagnosis and undertreatment, restraining market growth. The high cost of advanced diagnostic tools and technologies may also limit adoption in low-income countries, which is a significant constraint given that these countries carry the highest burden of NTDs.

Related Reports

https://www.strategicrevenueinsights.com/industry/carbon-free-brick-market

https://www.strategicrevenueinsights.com/industry/jlox-molecular-sieve-market

https://www.strategicrevenueinsights.com/industry/wet-food-pouch-market

https://www.strategicrevenueinsights.com/industry/kitchen-toilet-roll-converting-machines-market

https://www.strategicrevenueinsights.com/industry/multi-pocket-holders-market

Frequently Asked Questions

How big is the neglected tropical diseases diagnosis market?

The market was valued at USD 7.19 billion in 2025 and is projected to reach USD 12.35 billion by 2034, growing at a CAGR of 6.2%.

Which country leads the neglected tropical diseases diagnosis market?

Brazil leads the countries covered at approximately USD 1.2 billion, while Indonesia is the fastest-growing country covered, at a 10% CAGR.

What is driving growth in the neglected tropical diseases diagnosis market?

Growth is driven by the increasing prevalence of NTDs, technological advancements in diagnostic tools such as PCR and rapid diagnostic tests, and rising awareness and initiatives by governments and NGOs.

Who are the leading companies in the neglected tropical diseases diagnosis market?

Abbott, bioMérieux, and Thermo Fisher Scientific are named among the leading players, alongside Roche, BD, Cepheid, Sysmex, Standard Diagnostics, Bio-Rad Laboratories, and DiaSorin.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases